Breast Cancer

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and side effect management, among others.

A patient advocate says that patients with breast cancer may find it challenging to feel "normal," but reconstruction advancements may help.

An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with breast cancer.

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.

This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this is for you.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.

Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research.

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.